Singapore’s Health Sciences Authority stated on Wednesday it has approved clinical trials for a COVID-19 vaccine candidate dubbed LUNAR-COV19, developed by American biopharmaceutical company Arcturus Therapeutics and the local Duke-NUS Medical school, APA reports citing Teletrader.
According to the joint statement, human testing on 108 volunteers will be conducted in a fast manner.
Professor Ooi Eng Eong, deputy director of the emerging infectious diseases program at Duke-NUS, stated that "a single dose of this vaccine may be sufficient to trigger robust and durable immune responses."
Follow us on Telegram
t.me/apanewsaz
Follow us on Instagram
Follow us on Facebook
Follow us on Twitter
